Date: 2014-12-08
Type of information: Nomination
Compound:
Company: Pfizer (USA - NY)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 8, 2014, Pfizer announced two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. Pfizer has appointed Michael Linden, Ph.D., Professor at King’s College London and Director of the University College London Gene Therapy Consortium, who will be with the company for a two-year secondment to lead gene therapy research in the rare disease area.
- Effective December 1, 2014, Professor Michael Linden has joined Pfizer from his current position at King’s College London, for a two-year secondment to lead gene therapy research within the company’s rare disease research area. “The establishment of a gene therapy group under the leadership of Professor Linden will help Pfizer explore the potential of this important technology that could possibly benefit patients living with serious diseases,” said Kevin Lee, Ph.D., senior vice president and chief scientific officer of Pfizer’s Rare Disease Research Unit. “Professor Linden brings to Pfizer his extensive expertise in AAV technology obtained from over 20 years working in the field.”
Financial terms:
Latest news:
Is general: Yes
